Document is current
Any future updates will be listed below
-
Authors
Kimoto, Naoki
Miyashita, Yohei
Yata, Yutaka
Aketa, Takeshi
Yabumoto, Masami
Sakata, Yasushi
Washio, Takashi
Takashima, Seiji
Kitakaze, Masafumi https://orcid.org/0000-0001-5157-4213
-
Funding
Funding for this research was provided by:
Japan Heart Foundation (Grant to Kitakaze)
- License Information
-
More Information
Article History
Received: 31 May 2025
Accepted: 10 September 2025
First Online: 7 October 2025
Declarations
:
: The Grants-in-Aid from Japan Heart Foundation played no role in the study design, data collection, data analysis, and data interpretation or in the writing of the manuscript. The corresponding author assumed full data access and made the final decision to submit for publication.
: This retrospective observational study was approved by the external Ethics Committee of the Kinshukai Medical Group (approval number: 2024–3).
: The Study Committee decided that based on the Japanese Clinical Research Guidelines, obtaining informed consent from patients selected for inclusion was not necessary as this was a retrospective observational study. Instead, we made a public announcement following the Ethics Committee’s request and the Japanese Clinical Research Guidelines. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The authors affirm no use of any individual person’s data in any form.
: Relationships to industry do not exist for N. K., Y. M., Y. Y., T. A., M. Y., T. W., and S. T. Y. S. reports personal fees from AstraZeneca, personal fees from Otsuka Pharmaceutical, personal fees from Nippon Boehringer Ingelheim, personal fees from Novartis Pharma, personal fees from Bayer, grants from Nippon Boehringer Ingelheim, grants from Abbott Medical Japan, and grants from Otsuka Pharmaceutical outside the submitted work. M. K. reports personal fees from Daiichi-sankyo, personal fees from Viatris, grants and personal fees from Ono, grants from Novartis, grants and personal fees from Tanabe-mitubishi, grants from Takeda, grants and personal fees from Astra Zeneca, grants and personal fees from Boehringer-ingelheim, grants from Kowa, personal fees from Otsuka, and personal fees from Eli Lilly outside the submitted work.
